Ultra-low volume Target Siloam Biosciences as a partner for immunoassay optimization and microfluidic workflow automation, offering bundled sample handling, assay development, and customization services to expand their Optimiser platform uptake.

Point of care expansion Leverage TROVA and upcoming multiplexed desktop systems to position as a solution for clinics and hospitals seeking rapid, single-patient to multipatient diagnostics, presenting a pathway for OEM partnerships and clinical integration opportunities.

Multiplex potential Propose collaborative deals around multiplexed assays and automated desktop systems under government contracts (e.g., National Cancer Institute) to accelerate adoption, funding support, and shared development programs.

Affordability advantage Highlight cost-effective microfluidic platforms as a differentiator to healthcare buyers facing budget constraints, offering scalable pilot programs, volume pricing, and support for robotic automation compatibility.

Strategic flexibility Position Siloam for strategic alternatives by offering acquisition, licensing, or joint venture options that unlock broader manufacturing, distribution, and go-to-market capabilities with larger diagnostic players.